Targeted therapy of RET fusion-positive non-small cell lung cancer

Zixiong Shen; Binxu Qiu; Lin Li; Bo Yang; Guanghu Li

doi:10.3389/fonc.2022.1033484

Targeted therapy of RET fusion-positive non-small cell lung cancer

Front Oncol. 2022 Dec 13:12:1033484. doi: 10.3389/fonc.2022.1033484. eCollection 2022.

Authors

Zixiong Shen¹, Binxu Qiu², Lin Li¹, Bo Yang¹, Guanghu Li¹

Affiliations

¹ Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun, China.
² Department of Gastrointestinal Surgery, The First Hospital of Jilin University, Changchun, China.

Abstract

Lung cancer has very high morbidity and mortality worldwide, and the prognosis is not optimistic. Previous treatments for non-small cell lung cancer (NSCLC) have limited efficacy, and targeted drugs for some gene mutations have been used in NSCLC with considerable efficacy. The RET proto-oncogene is located on the long arm of chromosome 10 with a length of 60,000 bp, and the expression of RET gene affects cell survival, proliferation, growth and differentiation. This review will describe the basic characteristics and common fusion methods of RET genes; analyze the advantages and disadvantages of different RET fusion detection methods; summarize and discuss the recent application of non-selective and selective RET fusion-positive inhibitors, such as Vandetanib, Selpercatinib, Pralsetinib and Alectinib; discuss the mechanism and coping strategies of resistance to RET fusion-positive inhibitors.

Keywords: RET fusion; RET gene; cancer biology; non-small cell lung cancer (NSCLC); targeted therapy.

Publication types

Review